@FiercePharma: ICYMI earlier: Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi. News | Follow @FiercePharma
@EricPFierce: Amgen recalls Aranesp from UK, Russia, 7 other countries after polyester particles found in syringes. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Valeant, Pershing Square: Bring on the SEC insider trading probe. More | Follow @CarlyHFierce
> British investigator Peter Humphrey and his wife Yu Yinzeng, convicted for the investigative work they did for GlaxoSmithKline ($GSK), will not appeal their prison sentences of two-and-a-half and two years, respectively. Story
> U.S. Sen. Dick Durban (D-IL) has sent a letter to Lake Forest, IL-based Hospira ($HSP), urging it not to relocate its headquarters to Europe in a so-called tax inversion deal. Story | More
> The FDA has warned consumers not to buy Ebola "cures" online because they are fraudulent. Release
Medical Device News
@FierceMedDev: Researchers explore 'shape-shifting' material for facial reconstruction. More | Follow @FierceMedDev
@StacyALawrence: ICYMI: Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients. Story | Follow @StacyALawrence
@VarunSaxena2: RT @FierceMedicalDev: We're looking for fierce women at the top of their game in #medtech. Learn more about how to nominate. More | Follow @VarunSaxena2
@EmilyWFierce: Senate democrats outlining a proposal to crack down on corporate tax inversions. Story via The Wall Street Journal | Follow @EmilyWFierce
> Foundation Medicine teams with MD Anderson for new trial of cancer Dx. News
> Top U.S. senator urges Hospira to abandon inversion plans. Story
> FDA launches pilot program for qualification of medical device development tools. Article
> Researchers explore 'shape-shifting' material for facial reconstruction. More
Biotech News
@FierceBiotech: RT @NickPaulTaylor: EuroBiotech: NeuroSearch convicted of stock manipulation, VBL IPO unravels, Prosensa plans EMA filing and more. Report | Follow @FierceBiotech
@DamianFierce: CF biotech ProQR, pursuing a $75M IPO, employs a "happiness manager." | Follow @DamianFierce
@EmilyMFierce: Glaxo quietly edges toward Ebola vaccine but clinical barriers remain. FierceVaccines story | Follow @EmilyMFierce
> Teva tries laquinimod in Huntington's after repeated MS woes. Story
> CF biotech ProQR shoots for a $75M IPO to challenge Vertex. Article
> Achillion shoulders its way into the hep C race with strong early data. More
And Finally... A new study predicts that 40% of U.S. adults born in the decade between 2000 and 2011 will develop Type 2 diabetes in their lifetime, which is double the rate for men and 50% higher for women born two decades earlier. Story